Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 2 sites (Hefei, Anhui and 1 other locations) |
| Trial ID | NCT06690970 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga/18F-PSMA positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with PSMA-related diseases. Participants, who are adults with suspected or diagnosed malignant tumors, undergo PET/CT scans to assess the presence of cancerous lesions. The study measures various diagnostic metrics, including sensitivity and specificity, to determine the imaging technique's accuracy in identifying cancer. The findings aim to enhance diagnostic capabilities for prostate cancer and related conditions.
Who should consider this trial
Good fit: Ideal candidates include adult patients with suspected or newly diagnosed malignant tumors who are scheduled for a PSMA PET/CT scan.
Not a fit: Patients with non-malignant lesions or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of diagnosing prostate cancer and its metastases, leading to better treatment decisions.
How similar studies have performed: Other studies have shown promising results with similar imaging approaches, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Hefei, Anhui and 1 other locations
- The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (Recruiting)
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.